Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06119516

Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study.

The goal of this clinical trial is to test a personalized intervention aiming to optimize the mechanical ventilator settings in morbidly obese patients suffering from moderate to severe Acute Respiratory Distress Syndrome (ARDS). The intervention consists of personalized measurements and calculations of the different pressures inside the thorax. The main question to answer is:

• Will the evaluated esophageal pressure-guided strategy lead to different mechanical ventilator settings than suggested by a strategy largely used in ARDS patients in France?

A specific nasogastric probe permitting to measure esophageal pressure will monitor participants. Esophageal pressure will act as an indicator of the pleural pressure. Other respiratory signals displayed by the mechanical ventilators will also be acquired.

Further, ventilator settings will be adjusted to the evaluated esophageal pressure-guided strategy, with possible benefit of this personalized approach.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Angers, Angers, France

Loading trial locations.

About this study

The goal of this clinical trial is to test a personalized intervention aiming to optimize the mechanical ventilator settings in morbidly obese patients suffering from moderate to severe Acute Respiratory Distress Syndrome (ARDS). Mechanical ventilation is the cornerstone of the ARDS symptomatic treatment. Individualization of mechanical ventilator settings could improve prognosis mainly by preventing or decreasing accumulation of fluid in the lung and hemodynamic impairment. It is likely that class III obesity ARDS patients (defined by body mass index (BMI) > 40 kg/m2), could benefit from a highly personalized approach, based on esophageal pressure monitoring. These patients have significantly higher esophageal pressures, acting as an indicator of pleural pressure, than the general ARDS population, while these patients have rather normal mechanical characteristics of the chest wall. Such features could suggest innovative mechanical ventilator settings, by integrating esophageal pressures values, aiming to obtain a slightly positive transpulmonary pressure at the end of expiration.

The intervention consists of personalized measurements and calculations of the different pressures, including the esophageal one, inside the thorax.

The main question to answer is:

  • Will the evaluated esophageal pressure-guided strategy lead to different mechanical ventilator settings, mainly the positive end-expiratory pressure (PEEP) setting, than suggested by a PEEP-strategy largely used in ARDS patients in France?

A specific nasogastric probe permitting to measure esophageal pressure will monitor participants. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. Esophageal pressure will act as an indicator of the pleural pressure. Other respiratory signals displayed by the mechanical ventilators will also be acquired, permitting to calculate the trans-pulmonary pressures.

Further, ventilator settings will be adjusted to the evaluated esophageal pressure-guided strategy, with possible benefits of this personalized approach. The main benefits for the research participants will be the application of highly personalized mechanical ventilator settings, aiming mainly to select the best PEEP setting with the goal of optimization of opening the lung while avoiding the respiratory and hemodynamic consequences of excessive lung inflation. Monitoring of the end-inspiratory transpulmonary pressures will help to prevent excessive lung inflation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient (aged 18 years or older)
  • Class III morbid obesity (BMI > 40 kg/m2)
  • Moderate or severe ARDS criteria (according to the Berlin definition)
  • Less than 72 hours between fulfilling moderate or severe ARDS criteria and inclusion
  • Tracheal intubation and invasive mechanical ventilation
  • Informed consent (patient, next of kin), with possibility of an emergency procedure with deferred consent
  • Covid-19 and non-Covid-19 patients

Exclusion criteria

  • Contra-indication to nasogastric tube (uncontrolled coagulopathy, severe thrombocytopenia, nasal trauma, esophageal varices)
  • Order to limit life-sustaining therapy
  • ExtraCorporal Membrane Oxygenation (ECMO) in use
  • Invasive mechanical ventilation > 96 hours
  • Elevated intracranial pressure
  • Active air-leak: pneumothorax, pneumomediastinum
  • Pregnancy or breast feeding
  • Patient on state medical aid

Treatment and study plan

Esophageal pressure-guided strategy,

Other

A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.

Primary outcomes

  1. The absolute value of the difference between the PEEP levels determined by esophageal pressure-guided strategy and by the PEEP level indicated by the maximal recruitment arm of the ExPress trial

    Time frame: during the first 24 hours after inclusion

    To demonstrate that the evaluated esophageal pressure-guided strategy leads to significantly and clinically different mechanical ventilator settings (mainly PEEP setting) than the reference strategy.

Secondary outcomes

  1. The ratio between the arterial partial pressure of oxygen (PaO2) on the inspired fraction of oxygenFiO2): PaO2/FiO2 ratio

    Time frame: during the intervention

    To assess the efficacy of the esophageal pressure-guided strategy.

  2. The mortality rate of included patients.

    Time frame: Mortality rate will be determined at end of ICU stay, at Day 28 and at Day 90.

    To assess the efficacy and safety of the esophageal pressure-guided strategy.

  3. Number of days alive and free for invasive mechanical ventilation

    Time frame: The numbers of days alive and free for invasive mechanical ventilationwill be determined at Day-28 and Day-90

    To assess the efficacy of the esophageal pressure-guided strategy.

  4. Occurrence of pneumothorax

    Time frame: during the intervention

    To assess the safety of the esophageal pressure-guided strategy.

  5. Occurence of severe hemodynamic compromise defined by the need of vasoactive treatment

    Time frame: during the intervention

    To assess the safety of the esophageal pressure-guided strategy.

  6. Percentage of included patients with inability to insert the Nutrivent catheter

    Time frame: during the first 24 hours after inclusion

    To assess the feasibility of the esophageal pressure-guided strategy.

Study contacts

Contact information is provided by the study sponsor or research team.

Joséphine Braun

CONTACT

[email protected]

01 44 84 17 38

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Ministry of Health, France

Registry information

Acronym: TGV-MOA

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Nov 7, 2023
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.